High materiality7/10
Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
RBC Capital lowers DYN PT to $30; current price $19.72; upside remains.
- RBC Capital lowers DYN PT to $30; current price $19.72; upside remains.
Key facts
- 01
Target: $30
- 02
Posted price: $19.72
- 03
Analyst firm: RBC Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.